within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01B_AntiarrhythmicsClassIAndIii.C01BC09_Ethacizine;

model Ethacizine
  extends Pharmacolibrary.Drugs.ATC.C.C01BC09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C01BC09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ethacizine is a class I antiarrhythmic drug (mainly classified as a Vaughan-Williams class 1a antiarrhythmic agent) used to treat atrial and ventricular arrhythmias. It has been used in several countries, predominantly in Eastern Europe and Russia, but it is not widely approved or used in Western countries today due to concerns regarding pro-arrhythmic risks and safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adults receiving oral administration based on general class 1a antiarrhythmic pharmacokinetic profiles. No direct human PK studies published.</p><h4>References</h4><ol><li><p>Polyakov, AV, Svistunov, AA, Kondratenko, SN, Kovachevich, IV, Repenkova, LG, Savelyeva, MI, &amp; Kukes, VG (2020). Peculiarities of Pharmacokinetics and Bioavailability of Some Cardiovascular Drugs under Conditions of Antiorthostatic Hypokinesia. <i>Bulletin of experimental biology and medicine</i> 168(4) 465–469. DOI:<a href=&quot;https://doi.org/10.1007/s10517-020-04732-w&quot;>10.1007/s10517-020-04732-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32146624/&quot;>https://pubmed.ncbi.nlm.nih.gov/32146624</a></p></li><li><p>Preobrazhenskiĭ, DV, Sidorenko, BA, Kiktev, VG, Sidorov, RN, &amp; Andreĭchenko, TA (2005). [Atrial fibrillation: choice of the method of pharmacological cardioversion]. <i>Kardiologiia</i> 45(2) 72–80. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15798717/&quot;>https://pubmed.ncbi.nlm.nih.gov/15798717</a></p></li><li><p>Gneushev, ET, Kurapov, AP, Beliakova, GA, Zagrebin, SV, &amp; Starodubtsev, AK (1987). [Pharmacokinetic characteristics of ethacizine in patients with disorders of heart rhythm]. <i>Farmakologiia i toksikologiia</i> 50(4) 42–44. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3666115/&quot;>https://pubmed.ncbi.nlm.nih.gov/3666115</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ethacizine;
